Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-18 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2014-10-17 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in chemistry from the University of British Columbia, Canada, and a Ph.D. in chemistry from Simon Fraser University, Canada. |
| 2015-10-16 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in chemistry from the University of British Columbia, Canada, and a Ph.D. in chemistry from Simon Fraser University, Canada. He is currently President & Chief Executive Officer of ProNAi Therapeutics Inc., a publicly held drug development company advancing DNAi therapies for the treatment of cancer. |
| 2016-10-17 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in chemistry from the University of British Columbia, Canada, and a Ph.D. in chemistry from Simon Fraser University, Canada. |
| 2017-10-16 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2018-10-11 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2019-10-23 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2020-10-27 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2021-10-28 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. He has served as President and CEO of biotech companies focused on drug development. |
| 2022-10-27 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. |
| 2023-11-08 | Dr. Glover holds a B.Sc. in Chemistry, a M.Sc. in Chemistry, and a Ph.D. in Chemistry. |
| 2024-12-20 | Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. We believe Dr. Glover's extensive business experience and his drug development experience in the oncology field qualify him to serve on the Board. |
Data sourced from SEC filings. Last updated: 2026-02-03